Aug. 19 at 3:58 PM
$CDXS "A recent study indicates that Ozempic (semaglutide), a popular diabetes medication and weight-loss drug, could potentially be manufactured for significantly less than its current market price in the U.S.
Here's why and what it means for potentially reducing costs through enzymatic manufacturing:
Low Production Costs: The active ingredient, semaglutide, is found to be manufacturable at an estimated cost of 89 cents to
$4.73 per month's supply, including a profit margin. This is a stark contrast to the nearly
$1,000 monthly cost in the U.S. before insurance.
Enzymatic Production: The research suggests that using enzymatic processes in manufacturing could be key to achieving these lower production costs. While the exact details of the enzymatic manufacturing process are not fully public, this approach can potentially streamline production and reduce the need for expensive reagents and complex purification steps, ultimately driving down overall costs."
